Dietary ITCs (isothiocyanates) prevent cancer and show other bioactivities in vivo. As electrophiles, ITCs may covalently modify cellular proteins. Using a novel proteomics screen, we identified MIF (macrophage migration inhibitory factor) as the principal target of nutrient ITCs in intact cells. ITCs covalently modify the N-terminal proline residue of MIF and extinguish its catalytic tautomerase activity. MIF deficiency does not prevent induction of Phase 2 gene expression, a hallmark of many cancer chemopreventives, including ITCs. Due to the emerging role of MIF in the control of malignant cell growth and its clear involvement in inflammation, inhibition of MIF by nutrient ITCs suggests therapeutic strategies for inflammatory diseases and cancer.
INTRODUCTION
Dietary ITCs (isothiocyanates), such as PEITC (phenethyl ITC) and sulforaphane, are prevalent in cruciferous vegetables. Cancer prevention by ITCs is widely attributed to their ability to induce expression of detoxifying enzymes referred to as Phase 2 enzymes, including several of the GSTs (glutathione transferases) [1] . These enzymes are believed to promote the neutralization and excretion of carcinogens. However, ITCs inhibit tumour growth, even when administered after carcinogen insult [2, 3] and in xenograft tumour models [4] , when protection from mutagenic damage cannot explain cancer prevention. Other mechanisms, such as induction of apoptosis [5] or host-tumour interactions, present viable alternate mechanisms of cancer prevention.
Since ITCs are reactive electrophilic compounds, we hypothesized that they would covalently modify cellular target proteins. We undertook a proteomics screen to purify proteins covalently modified by ITCs. We identified MIF (macrophage migration inhibitory factor) as the predominant cellular target of ITC modification. As the first cytokine to be identified [6, 7] , MIF has been extensively characterized for its critical role in inflammation. Studies using neutralizing antibodies or MIFdeficient animals showed that inhibition of MIF can ameliorate disease processes in animal models of arthritis and inflammatory bowel disease, among many others [8, 9] . Moreover, MIF is overexpressed in cancers (e.g. [10, 11] ), and MIF expression correlates with tumour aggressiveness [12] . Evidence in vitro has suggested that MIF is required for cellular transformation [13] , and that loss of MIF expression reduces the growth of tumours in animal models [14, 15] .
MIF is a 12 kDa protein with an enzymatic keto-enol tautomerase activity [16] . Although the natural tautomerase substrate remains unknown, tautomerase activity contributes to biological activities associated with MIF [17] , leading to the conclusion that pharmacological agents that block tautomerase activity may have broad applicability. We have demonstrated that dietary nutrient ITCs covalently modified MIF and inhibited its tautomerase activity, suggesting that they may represent valuable natural product inhibitors of MIF function in human disease.
EXPERIMENTAL Cell culture, plasmids and reagents
HeLa cells were cultured in DMEM (Dulbecco's modified Eagle's medium)/10 % FCS (foetal calf serum) and penicillin (100 units/ml)/ streptomycin (100 μg/ml). MEFs (mouse embryo fibroblasts) and HepG2 cells were cultured in DMEM/10 % FCS plus antibiotics as above. Expression plasmids for MIF were prepared in pcDNA3 (Stratagene) by PCR amplification of the MIF coding sequence. In some cases, the MIF coding region was fused to a CBD (chitin-binding domain) tag at the C-terminus for purification on chitin beads. Recombinant MIF with a similar CBD tag removed using an intervening thrombin cleavage site was produced in Escherichia coli BL21(DE3) cells using the pET11b vector (Novagen). All PCR-amplified coding regions were fully sequenced. MIF-directed SMARTpool siRNAs (small interfering RNAs), along with a control non-targeting siRNA pool, were purchased from Dharmacon. Anti-MIF antibody was from Santa Cruz Biotechnology and anti-biotin antibody from Cell Signaling. 
Figure 1 Proteomics screen for protein targets of covalent ITC modification
Bio-ITC structure (A) and scheme of the competition-based screen (B). In cells pretreated with PEITC, ITC target sites are occupied by the natural ITC (P). After lysis and labelling with Bio-ITC (B), these specific target sites are unavailable, although non-specific proteins (N) may be labelled. Detection of Bio-ITC will show specific and non-specific proteins. A, all other unmodified proteins; SA-PD, streptavidin pull-down sample. Proteins detected in the samples prepared from the untreated cells, but absent from the PEITC-treated cells, represent specific targets of the natural ITC in intact cells. (C) A representative labelling experiment. HeLa cells were left untreated or pretreated with 250 μM PEITC to promote complete modification of potential target proteins. Lysates were labelled with Bio-ITC (BioITC) in vitro, and labelled proteins were detected by SDS/PAGE with HRP-conjugated streptavidin. The predominant target of Bio-ITC modification was a low-molecular-mass protein of less than 29 kDa, indicated by the double arrowheads; labelling was completely inhibited by pretreatment of the intact cells with PEITC.
ITC proteomics
Bio-ITC (biotin-ITC) was synthesized as described previously [18] , with modifications as described in [19] . HeLa cells were left untreated or pre-treated for 30 min with 250 μM PEITC to promote complete modification of potential target proteins, followed by Dounce homogenization in 25 mM Hepes containing aprotinin and leupeptin (2.5 μg/ml for each). Clarified lysates were labelled in vitro with Bio-ITC [500 μM for 1 h at room temperature (20 • C)] and then stopped by the addition of Laemmli sample buffer. Lysates were separated on SDS/PAGE gels and the labelled proteins detected using HRP (horseradish peroxidase)-conjugated streptavidin (Zymed) or anti-biotin antibody (Cell Signaling). For purification, the lysates were dialysed against 25 mM Hepes to remove free Bio-ITC, and the labelled proteins were purified using streptavidin-Sepharose (Amersham), separated by SDS/PAGE and detected by silver staining. The lowmolecular-mass band was excised for analysis.
Mass determination of MIF and PEITC-MIF protein
The rMIF (recombinant MIF) protein was treated with PEITC in vitro until tautomerase activity was completely quenched. Intact rMIF (1 μg/μl) and PEITC-labelled rMIF were infused separately into an LTQ mass spectrometer (Thermo Fisher Scientific) at 1-3 μl per min. MS spectra were collected and the protein-chargestate envelope for each was de-convoluted to determine the mass with an accuracy of approx. + − 5 Da.
MS identification of the modification site
PEITC-labelled MIF was digested with trypsin (Roche) and loaded on to a 100 μm i.d. (internal diamater) fused silica precolumn self-packed with irregular (5-25 μm, 120 Å) reversephase phenyl beads (Phenomenex). The pre-column was attached to an analytical 75 μm i.d. PicoFrit column (New Objective, Woburn, MA, U.S.A.) self-packed with regular (5 μm, 120 Å) reverse-phase phenyl beads (Phenomenex). Peptides were eluted using a gradient of 0-70 % acetonitrile in 0.1 % acetic acid and directly electrosprayed into the LTQ mass spectrometer. The duty cycle was a full scan (300-2000 m/z) followed by MS 2 (tandem MS) CID (collision-induced dissociation) fragmentation of the five most abundant ions with dynamic exclusion. MS 2 scans identified using SEQUEST were manually verified.
MIF tautomerase activity
The substrate [16] was prepared by mixing equal volumes of 4 mM L-3,4-dihydroxyphenylalanine methyl ester hydrochloride (D-dopachrome; Sigma) and 8 mM sodium (meta)periodate (Sigma) and incubating at room temperature for 5 min. The cell lysates or rMIF were assayed in 25 mM phosphate buffer (pH 6.0)/1 mM EDTA containing 100 μl/ml freshly prepared substrate. Decolorization was monitored over time by measuring the absorbance at 475 nM.
ARE (antioxidant-responsive element)-luciferase and Phase 2/ARE-driven gene induction in MEFs
HepG2 cells, seeded in 24-well plates, were transfected with an ARE-driven luciferase plasmid with either control siRNA or MIF-targeting siRNAs (50 pmol). After 24 h, the medium was replaced with fresh medium containing various concentrations of sulforaphane or DMSO vehicle. Cells were incubated for an additional 24 h and then harvested in cell culture lysis reagent (Promega) and assayed for luciferase activity. For ITC-induced gene expression in MEFs, wild-type or MIF-deficient MEFs were treated with 10 μM sulforaphane or vehicle control for 12 h and the RNA was prepared using TRIzol ® Reagent (Invitrogen). RNA was quantified and 1 μg of RNA was reverse-transcribed using the iScript kit (Bio-Rad). Real-time PCR analysis was performed using IQ SYBR Green Supermix and an iCycler Instrument (Bio-Rad).
ADDITIONAL METHODS
Further methods can be found in the Supplementary Online Data at http://www.BiochemJ.org/bj/423/bj4230315.add.htm.
RESULTS

Proteomics screen for targets of ITC modification
We synthesized a biotin-based ITC affinity probe, Bio-ITC, ( Figure 1A ), and used a competition assay to identify protein targets of natural ITCs, as shown in Figure 1 (B). We first incubated intact cells with an excess of the natural ITC, PEITC, so that covalent protein targets of PEITC would be fully modified. Then PEITC-treated cells and untreated control cells were lysed, and the protein extracts were reacted with Bio-ITC in vitro. Proteins that were fully modified by PEITC in cells were not labelled with Bio-ITC, since the target sites were occupied. Therefore the biotin-labelled proteins present in untreated cell lysates, but absent in the PEITC-pretreated cell lysates, represent targets of PEITC in intact cells.
Using this screen, a single low-molecular-mass protein of less than 29 kDa accounted for the majority of the total Bio-ITC labelling of the proteins in the cells ( Figure 1C ). This labelled protein was completely absent from samples pretreated with PEITC, suggesting that it was quantitatively modified under these conditions. Dose-response experiments showed that Bio-ITC labelling of this small protein was nearly completely inhibited by 30 min of incubation with as little as 25 μM PEITC, and was partially inhibited at even lower doses (see Supplementary Fig ures S1 and S2 at http://www.BiochemJ.org/bj/423/bj4230315add. htm). Similar results were obtained with other ITCs, including sulforaphane (for example, see Supplementary Figure S2 ).
Bio-ITC-labelled proteins, purified from untreated or PEITCpretreated lysates by streptavidin-affinity chromatography, were separated on an SDS/PAGE gel (results not shown), and a low-molecular-mass band present in the untreated sample, but absent from the PEITC-pretreated sample, was excised and subjected to tryptic peptide fingerprinting using LC-MS (liquid chromatography MS). We identified a peptide in the sample (LLCGLLAER) that was unique to the human genome and identical to a predicted peptide of MIF. 
ITCs covalently modify MIF on Pro-2
To confirm the identification of MIF as the PEITC-target protein, we depleted MIF from HeLa cells using siRNA and measured the effect on Bio-ITC labelling of the small protein ( Figure 2A) . Depletion of the MIF protein resulted in a concomitant loss of the biotin-labelled band. We made expression plasmids for MIF that fuse a CBD tag to the C-terminus of MIF. MIF-CBD expressed in transfected cells was efficiently labelled by Bio-ITC treatment of cell lysates, and this labelling was completely inhibited by pretreatment of intact cells with PEITC ( Figure 2B ). These results confirm that MIF is a covalent target of dietary ITCs.
MS showed a mass of the intact ITC-modified rMIF protein consistent with one ITC moiety per polypeptide (see Supplementary Figure S3 at http://www.BiochemJ.org/bj/423/ bj4230315add.htm). To determine the site of ITC modification, rMIF protein was incubated with PEITC, trypsinized and then analysed by LC-MS 2 . We found spectra from a single tryptic peptide that contained the predicted 163 Da addition; this was on a peptide containing the PEITC label on the N-terminal proline at position 2 ( Figure 3A) , following cleavage of the initiator methionine residue. Separately, rMIF was treated with other ITCs, including sulforaphane ( Figure 3B ). In each case, ITC modification of the expected mass was found on Pro-2. Therefore rMIF is singly modified on Pro-2 by ITCs in vitro.
To confirm the specificity of labelling in intact mammalian cells, we made an expression plasmid encoding MIF with Pro-2 replaced with a glycine residue (MIF-P2G). MIF-P2G was not labelled with Bio-ITC ( Figure 4A ), demonstrating that Pro-2 is required for the modification of MIF in mammalian cells. 
ITCs inhibit MIF tautomerase activity
The MIF protein has enzymatic tautomerase activity which has been shown previously to require Pro-2 [16] . Incubation of rMIF with PEITC inhibited the tautomerase activity in a concentrationdependent manner ( Figure 4B ). In vitro, rMIF is exquisitely sensitive to inhibition by PEITC, with an IC 50 for tautomerase inhibition of less than 1 μM, as might be expected for a covalent inhibitor. Similar results were obtained with sulforaphane (results not shown).
In intact HeLa cells, PEITC treatment resulted in the concentration-dependent inhibition of tautomerase activity ( Figure 4C) , with an IC 50 for inhibition between 5 and 6 μM.
Inhibition of tautomerase in HeLa cells by sulforaphane was even more efficient, with an IC 50 between 1 and 2 μM ( Figure 4D ). As MIF is the only protein contributing to the tautomerase activity measured under our assay conditions in HeLa cell lysates (see Supplementary Figure S4 
MIF deficiency does not alter the induction of Phase 2/ARE-dependent genes by ITCs
MIF has been proposed to play a role in regulation of several transcription factors, including AP-1(activator protein 1) [20] . Therefore ITC modification of MIF could explain, at a molecular level, the induction of Phase 2 genes and other ARE-driven gene expression in cells exposed to ITC. However, depletion of MIF with siRNA did not alter the activation of ARE-dependent transcription in response to sulforaphane treatment ( Figure 5A ). Moreover, MEFs prepared from MIF −/− embryos were not impaired in their ability to induce the transcription of Phase 2 or other ARE-dependent genes in response to sulforaphane treatment ( Figure 5B ). Together, these results suggest that the modification and inhibition of MIF is not involved in the induction of Phase 2 gene expression in response to ITC treatment.
DISCUSSION
The role of MIF as an essential mediator of disease, particularly inflammatory disease, has been long appreciated (for example, [8, 9] ). In animal models, neutralization of MIF with antibodies and/or experiments in MIF-deficient mice have supported the conclusion that maintenance of functional MIF is required for disease progression. Thus inhibition of MIF using ITCs as nutritional or pharmacological agents may provide a therapeutic intervention in a broad range of disease processes, and different inhibitory efficiencies for distinct ITC agents may enable optimization of therapeutic modalities. Furthermore, biochemical inhibition of the MIF tautomerase should serve as a biomarker of ITC therapeutic action in target organs or for pharmacokinetic measurements in biological fluids.
Importantly, the low micromolar concentration of ITCs necessary for inhibition of MIF in cells is similar to levels found in the circulation of human subjects after oral consumption of broccoli sprouts, a rich source of dietary ITCs [21] . Although ITCs are metabolized by conjugation to glutathione in vivo, glutathione-conjugated ITCs, and the terminal metabolite, Nacetylcysteine-conjugated ITCs, are as effective as unconjugated ITCs for MIF tautomerase inhibition (see Supplementary Figure S5 at http://www.BiochemJ.org/bj/423/bj4230315add.htm, and results not shown). Thus metabolism does not limit the potential utility of ITCs as anti-MIF human therapeutics.
The tautomerase activity of MIF has been correlated with its biological activities. However, the natural substrate of the MIF tautomerase remains unknown. This has led at least one group to suggest that the tautomerase activity cannot be relevant to the biological activities [22] , although these same workers simultaneously reported the merit of a synthetic competitive tautomerase inhibitor. This inhibitor has proven effective in several animal models of MIF-dependent disease (for example, [22, 23] ). The ITCs offer an advantage over this competitive Previous reports have shown that MIF expression in cells is required for malignant transformation by combinations of dominant oncogenes [13] , and that overexpression of MIF can suppress cell death induced by p53 expression [24] . Because of these observations, it is likely that suppression of part of the cancer phenotype by ITCs may be a direct result of inhibition of MIF function in tumour cells. Alternatively, the role for MIF in cancer prevention may reflect disruption of the stimulatory interactions between cancer cells and the host, for example through inhibition of the inflammatory cells that contribute to the tumour micro-environment. This possibility is supported by the numerous reports of cancer prevention in animals, and the relative paucity of reports of tumour-cell-growth interruption by the same agents, except at supra-physiological doses.
As an efficient natural product inhibitor of MIF tautomerase, ITCs represent a safe and effective class of inhibitors that could rapidly reach clinical application for a number of diseases in which MIF has been identified as an attractive therapeutic target. 
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EXPERIMENTAL
Identification of the low-molecular-mass Bio-ITC target protein by MS
Samples labelled as described in Figure 1 (C) in the main paper were dialysed to remove unincorporated Bio-ITC and biotinlabelled proteins purified by binding to streptavidin beads, which were then washed extensively, and the proteins were eluted in SDS sample buffer. Purified proteins were separated by SDS/PAGE (12.5 % gel) and detected by silver staining. A low-molecularmass silver-stained band that was present in the untreated lysates, but absent in the PEITC-pretreated samples, was cut from the gel, washed and destained in 50 % methanol overnight. The gel pieces were dehydrated in acetonitrile, followed by sequential reduction (in 10 mM dithiothreitol) and alkylation (50 mM iodoacetamide). The gel pieces were washed, dried by vacuum centrifugation and then rehydrated in 20 ng/μl trypsin in 50 mM ammonium bicarbonate and incubated for 10 min on ice. Excess solution was removed and replaced with 20 μl of ammonium bicarbonate and the digestion incubated overnight at 37
• C. Trypsinized peptide were extracted from the gel piece in two 30 μl aliquots of 5 % formic acid in 50 % acetonitrile and then dried for LC-MS analysis on a Finnigan LCQ ion-trap mass spectrometer system with a Protana nanospray ion source. Chromotography was carried out on a 8 cm (length) × 75 μm (i.d.) reverse-phase capillary column self-packed with Phenomenex Jupiter 10 μm phenyl medium, eluted with an acetonitrile/0.1 M acetic acid gradient (flow rate, 0.25 μl/min). Full-scan mass spectra (for molecularmass determination) and product ion spectra (for amino-acid sequencing) were collected in sequential scans. The data were searched using the SEQUEST search algorithm (Thermo Fisher Scientific).
siRNA transfection
A pool of MIF-targeting siRNAs and a control non-targeting siRNA pool were purchased from Dharmacon. Pooled siRNAs (100 pmol/well) were transfected into HeLa cells, seeded in 12-well plates, using Lipofectamine TM 2000 according to the manufacturer's instructions. Cells were treated and labelled as described in the Figure legends.
MIF-targeting shRNA (small-hairpin RNA)
The MIF-targeting shRNA expression plasmid was prepared in the pSIREN Retro Q retroviral vector (Clontech). Oligonucleotides (Invitrogen) were annealed, gel-purified and ligated into the vector that had been digested with BamHI and EcoRI. The oligonucleotide sequences were as follows: oligo 1, gatccATGCCGATGTTCATCGTAATTCAAGAGATTACGATGAACATCGGCATTTTTTTACGCGTg; oligo 2: aattcACGC-GTAAAAAAATGCCGATGTTCATCGTAATCTCTTGAATTACGATGAACATCGGCATg.
Virus pseudotyped with the VSV (vesicular-stomatitis virus) glycoprotein was prepared by transfection of amphotropic retroviral packaging cells in six-well plates with FuGENE TM (Roche) in 2 ml of medium per well. Post-transfection (48 h), supernatants were harvested, centrifuged (12 000 g, 5 min, 4
• C) and frozen in 500 μl aliquots at − 80
• C. One aliquot of supernatant was thawed, re-centrifuged (12 000 g, 5 min, 4
• C) and used to infect HeLa cells in the presence of 4 μg/ml Polybrene overnight at 37
• C. Post-transfection (48 h), transduced cells were selected in 1 μg/ml puromycin to generate a pool of MIF-depleted cells. Efficient knockdown was confirmed by tautomerase assay and Western blotting. 
Preparation of rMIF
An expression plasmid for rMIF was constructed in the pET11b plasmid (Novagen). The MIF coding region was fused at its C-terminus to the CBD tag with an intervening thrombin recognition sequence (LVPRGS) and the sequence confirmed. The plasmid was transformed into E. coli BL21(DE3), and protein expression induced overnight at room temperature using with 50 μM IPTG (isopropyl β-D-thiogalactoside). The bacteria were pelleted (6000 g, 10 min, 4
• C), lysed in TNE5 [10 mM Tris/HCl (pH 7.5), 150 mM NaCl and 5 mM EDTA] with 1 % Igepal detergent (Sigma) by sonication. Washed chitin bead slurry (300 μl) (New England BioLabs) was added to clarified lysate and this was then incubated at 4
• C on a rotating mixer. Beads were washed five times with TNE5/1 % Igepal and then four times with PBS. Protein was cleaved from beads by incubating with 2.5 units of thrombin in 500 μl of PBS overnight at room temperature. Beads were removed using poly(ethylene) spin filters and the protein concentration quantified by the Bradford assay. Purity was confirmed by SDS/PAGE followed by Coomassie staining. 
Preparation of wild-type and MIF
−/− MEFs MIF heterozygous Balb/c mice [1] were obtained from Jackson Laboratories, following recovery from cryopreserved stocks. A breeding colony was established and all experimentation performed under the protocols approved by the University of Virginia, Institutional Animal Care and Use Committee. Embryos were harvested at day 13.5 from a heterozygous mating. MEFs were prepared by removing the head and digesting the remainder of the embryo in trypsin for 1 h at 37 • C. MEFs were cultured in DMEM/10 % FCS supplemented with penicillin (100 units/ml)/streptomycin (100 μg/ml) and gentamycin (15 μg/ml). Embryo heads were digested in DirectPCR lysing reagent (Viagen) with 200 μg/ml proteinase K and used for genotyping. Primary MEFs were used within the first seven passages.
Oligonucleotide pimers for real-time RT-PCR (reverse transcription-PCR)
The primers as are described in [2] , except where indicated. HO-1 (haem oxygenase 1) [3] : forward, 5 -CCCACCAAGTTCAAA-CAGCTC-3 ; reverse, 5 -AGGAAGGCGGTCTTAGCCTC-3 . VLDLR (very-low-density lipoprotein receptor) [4] : forward, 5 -CGGAGCCAAGAGGAAGTTCC-3 ; reverse, 5 -CGCCC-CAGTCTGACCAGTAA-3 . GSTA4: forward, 5 -GCCAAGT-ACCCTTGGTTGAA-3 ; reverse, 5 -AATCCTGACCACCTCA-ACA-3 . GSTMu: forward, 5 -CTCCCGACTTTGACAGAAGC-3 ; reverse, 5 -CAGGAAGTCCCTCAGGTTTG-3 . NQO1
Figure S4 MIF is the only tautomerase activity measured in HeLa cells
HeLa cells were infected with retrovirus encoding an shRNA directed against MIF. Stably transduced cells were selected using puromycin, and the tautomerase activity of the resultant pools was measured. MIF was efficiently depleted from the shRNA-transduced cells (MIF KD), as reflected in the complete loss of tautomerase activity (A) and the absence of MIF in the immunoblot (B). The MIF-depleted cells were transiently transfected with MIF expression constructs engineered to escape shRNA targeting (WTesc for wild-type MIF and P2Gesc for the MIF-P2G mutant). Introduction of wild-type MIF, but not the catalytically inactive P2G mutant, partially restored tautomerase activity, suggesting that MIF is the only tautomerase in HeLa cells that contributes to the tautomerase activity measured under these assay conditions. (B) was prepared from a single gel and single exposure, with one lane removed, as indicated by the vertical line. IB, immunoblot; recon, MIF reconstituted cells.
[NAD(P)H-quinone oxidoreductase 1]: forward, 5 -CATTCTG-AAAGGCTGGTTTGA-3 ; reverse, 5 -CTAGCTTTGATCTGG-TTGTCAG-3 . Actin: forward, 5 -CCCAGAGCAAGAGAG-GTATC-3 ; reverse, 5 -AGAGCATAGCCCTCGTAGAT-3 .
Figure S5 Glutathione conjugation does not alter MIF inhibitory activity of PEITC
GSH was prepared at 100 mM in 50 mM Tris/HCl, pH 7.8 (yielding a near neutral pH). PEITC was incubated with a 1000-fold excess of GSH at room temperature for 3 h. rMIF (240 ng) was added and the incubation continued for an additional 30 min, then assayed for tautomerase activity. Preconjugation of PEITC with glutathione did not affect its ability to inhibit MIF tautomerase activity, as reflected in the overlapping decolorization curves. Untx, untreated.
Correlation of tautomerase inhibition with competition for Bio-ITC labelling
HeLa cells, seeded in six-well plates, were treated with the indicated concentrations of SFN ( Figure S2A ) or PEITC (Figure S2B) for 30 min at 37
• C. The cells were lysed in 250 μl of 25 mM Hepes (pH 7.4)/0.4 M NaCl/1 % Igepal supplemented with protease inhibitors (aprotinin and leupeptin, both at 2.5 μg/ml). Clarified lysate (10 μl) was assayed for tautomerase activity, as described above. Lysate (25 μl) was labelled with 25 μM Bio-ITC for 1 h at room temperature. Samples were separated by SDS/PAGE and labelled protein detected with antibiotin antibody. A membrane was immunoblotted with anti-MIF antibody in parallel to demonstrate equivalent amounts of protein.
